Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K Samara
Evaluating the Annual Cost Per Response Rate of Pirfenidone and Nintedanib for the Treatment of Patients With Idiopathic Pulmonary Fibrosis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Psy105 - Cost-Utility of Nintedanib Versus Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis: A Belgian Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prs41 - Cost-Effectiveness of Pirfenidone for the Treatment of Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Idiopathic Pulmonary Fibrosis and Pirfenidone
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis
Annals of Thoracic Surgery
Respiratory Medicine
Pulmonary
Cardiovascular Medicine
Surgery
Cardiology
Efficacy of Pirfenidone in Patients With Advanced-Stage Idiopathic Pulmonary Fibrosis
Internal Medicine
Internal Medicine
Medicine
Efficacy and Safety of Nintedanib in Patients With Advanced Idiopathic Pulmonary Fibrosis
BMC Pulmonary Medicine
Pulmonary
Respiratory Medicine
Pirfenidone Should Be Prescribed for Patients With Idiopathic Pulmonary Fibrosis: Table 1
Thorax
Pulmonary
Respiratory Medicine
Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: Nationwide Danish Results
European Clinical Respiratory Journal
Remarkable Improvement in a Patient With Idiopathic Pulmonary Fibrosis After Treatment With Nintedanib
Internal Medicine
Internal Medicine
Medicine
